CalciMedica (NASDAQ:CALC) Earns Buy Rating from HC Wainwright

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $16.00 price target on the stock.

CalciMedica Trading Down 6.2 %

CALC stock opened at $2.13 on Tuesday. The firm has a 50-day moving average of $2.77 and a two-hundred day moving average of $3.44. CalciMedica has a 12 month low of $1.86 and a 12 month high of $6.27. The company has a market cap of $28.72 million, a price-to-earnings ratio of -1.97 and a beta of 1.20.

Hedge Funds Weigh In On CalciMedica

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cetera Investment Advisers boosted its holdings in CalciMedica by 37.1% in the 4th quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock valued at $60,000 after purchasing an additional 4,566 shares during the last quarter. Atria Investments Inc lifted its holdings in CalciMedica by 28.3% in the fourth quarter. Atria Investments Inc now owns 34,012 shares of the company’s stock valued at $120,000 after acquiring an additional 7,509 shares during the last quarter. PVG Asset Management Corp acquired a new position in CalciMedica in the third quarter valued at approximately $67,000. Millennium Management LLC grew its position in CalciMedica by 30.5% in the fourth quarter. Millennium Management LLC now owns 72,057 shares of the company’s stock worth $255,000 after acquiring an additional 16,824 shares during the period. Finally, Geode Capital Management LLC increased its stake in CalciMedica by 51.2% during the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock worth $295,000 after acquiring an additional 22,525 shares during the last quarter.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.